CLOROX CO /DE/, 10-Q filed on 4/30/2021
Quarterly Report
v3.21.1
Cover Page - shares
9 Months Ended
Mar. 31, 2021
Apr. 16, 2021
Cover [Abstract]    
Document Type 10-Q  
Document Quarterly Report true  
Document Period End Date Mar. 31, 2021  
Document Transition Report false  
Entity File Number 1-07151  
Entity Registrant Name THE CLOROX COMPANY  
Entity Incorporation, State or Country Code DE  
Entity Tax Identification Number 31-0595760  
Entity Address, Address Line One 1221 Broadway  
Entity Address, City or Town Oakland  
Entity Address, State or Province CA  
Entity Address, Postal Zip Code 94612-1888  
City Area Code 510  
Local Phone Number 271-7000  
Title of 12(b) Security Common Stock - $1.00 par value  
Trading Symbol CLX  
Security Exchange Name NYSE  
Entity Current Reporting Status Yes  
Entity Interactive Data Current Yes  
Entity Filer Category Large Accelerated Filer  
Entity Small Business false  
Entity Emerging Growth Company false  
Entity Shell Company false  
Entity Common Stock, Shares Outstanding   124,372,035
Entity Central Index Key 0000021076  
Amendment Flag false  
Current Fiscal Year End Date --06-30  
Document Fiscal Period Focus Q3  
Document Fiscal Year Focus 2021  
v3.21.1
Condensed Consolidated Statements of Earnings and Comprehensive Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Income Statement [Abstract]        
Net sales $ 1,781 $ 1,783 $ 5,539 $ 4,738
Cost of products sold 1,007 951 3,008 2,604
Gross profit 774 832 2,531 2,134
Selling and administrative expenses 237 269 744 690
Advertising costs 200 184 566 461
Research and development costs 32 39 104 103
Goodwill, trademark and other asset impairments 329 0 329 0
Interest expense 25 24 74 74
Other (income) expense, net 10 19 (85) 16
Earnings (losses) before income taxes (59) 297 799 790
Income taxes 0 56 180 161
Net earnings (losses) (59) 241 619 629
Less: Net earnings attributable to noncontrolling interests 2 0 6 0
Net earnings (losses) attributable to Clorox $ (61) $ 241 $ 613 $ 629
Net earnings (losses) per share attributable to Clorox        
Basic net earnings per share (in dollars per share) $ (0.49) $ 1.92 $ 4.86 $ 5.01
Diluted net earnings per share (in dollars per share) $ (0.49) $ 1.89 $ 4.78 $ 4.94
Weighted average shares outstanding (in thousands)        
Basic (in shares) 125,610 125,661 126,057 125,641
Diluted (in shares) 125,610 127,328 128,030 127,236
Comprehensive income (loss) $ (37) $ 186 $ 706 $ 575
Less: Total comprehensive income attributable to noncontrolling interests 2 0 6 0
Total comprehensive income (loss) attributable to Clorox $ (39) $ 186 $ 700 $ 575
v3.21.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Millions
Mar. 31, 2021
Jun. 30, 2020
Current assets    
Cash and cash equivalents $ 492 $ 871
Receivables, net 643 648
Inventories, net 688 454
Prepaid expenses and other current assets 139 47
Total current assets 1,962 2,020
Property, plant and equipment, net of accumulated depreciation and amortization of $2,351 and $2,224, respectively 1,251 1,103
Operating lease right-of-use assets 328 291
Goodwill 1,574 1,577
Trademarks, net 694 785
Other intangible assets, net 246 109
Other assets 386 328
Total assets 6,441 6,213
Current liabilities    
Current maturities of long-term debt 300 0
Current operating lease liabilities 74 64
Accounts payable and accrued liabilities 1,445 1,329
Income taxes payable 0 25
Total current liabilities 1,819 1,418
Long-term debt 2,483 2,780
Long-term operating lease liabilities 305 278
Other liabilities 819 767
Deferred income taxes 77 62
Total liabilities 5,503 5,305
Commitments and contingencies
Stockholders’ equity    
Preferred stock: $1.00 par value; 5,000,000 shares authorized; none issued or outstanding 0 0
Common stock: $1.00 par value; 750,000,000 shares authorized; 130,741,461 and 158,741,461 shares issued as of March 31, 2021 and June 30, 2020, respectively; and 124,359,712 and 126,198,606 shares outstanding as of March 31, 2021 and June 30, 2020, respectively 131 159
Additional paid-in capital 1,190 1,137
Retained earnings 1,086 3,567
Treasury stock, at cost: 6,381,749 and 32,542,855 shares as of March 31, 2021 and June 30, 2020, respectively (1,111) (3,315)
Accumulated other comprehensive net (loss) income (553) (640)
Total Clorox stockholders’ equity 743 908
Noncontrolling interests 195 0
Total stockholders’ equity 938 908
Total liabilities and stockholders’ equity $ 6,441 $ 6,213
v3.21.1
Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - USD ($)
$ in Millions
Mar. 31, 2021
Jun. 30, 2020
Statement of Financial Position [Abstract]    
Property, plant and equipment, accumulated depreciation and amortization $ 2,351 $ 2,224
Preferred stock, par value (in dollars per share) $ 1.00 $ 1.00
Preferred stock, shares authorized (in shares) 5,000,000 5,000,000
Preferred stock, shares issued (in shares) 0 0
Preferred stock, shares outstanding (in shares) 0 0
Common stock, par value (in dollars per share) $ 1.00 $ 1.00
Common stock, shares authorized (in shares) 750,000,000 750,000,000
Common stock, shares issued (in shares) 130,741,461 158,741,461
Common stock, shares outstanding (in shares) 124,359,712 126,198,606
Treasury stock, shares (in shares) 6,381,749 32,542,855
v3.21.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Millions
9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Operating activities:    
Net earnings $ 619 $ 629
Adjustments to reconcile net earnings to net cash provided by operations:    
Depreciation and amortization 157 133
Stock-based compensation 52 37
Deferred income taxes (21) 5
Goodwill, trademark and other asset impairments 329 0
Other (53) 26
Changes in:    
Receivables, net 46 (102)
Inventories, net (220) 50
Prepaid expenses and other current assets (29) (6)
Accounts payable and accrued liabilities 94 53
Operating lease right-of-use assets and liabilities, net (1) 7
Income taxes payable / prepaid (80) (26)
Net cash provided by operations 893 806
Investing activities:    
Capital expenditures (232) (158)
Businesses acquired, net of cash acquired (85) 0
Other (24) 13
Net cash used for investing activities (341) (145)
Financing activities:    
Notes and loans payable, net 0 234
Treasury stock purchased (605) (225)
Cash dividends paid to Clorox stockholders (420) (399)
Cash dividends paid to noncontrolling interests (18) 0
Issuance of common stock for employee stock plans and other 99 129
Net cash used for financing activities (944) (261)
Effect of exchange rate changes on cash, cash equivalents, and restricted cash 10 (8)
Net increase (decrease) in cash, cash equivalents, and restricted cash (382) 392
Cash, cash equivalents, and restricted cash:    
Beginning of period 879 113
End of period $ 497 $ 505
v3.21.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
9 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2021 and 2020, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2020, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.

Recently Issued Accounting Standards

Recently Issued Accounting Standards Not Yet Adopted

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which improves consistency in the application of accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and by clarifying and amending existing guidance. The standard will be effective for the Company beginning in the first quarter of fiscal year 2022, with early adoption permitted. The amendments that are related to changes in ownership of foreign equity method investments or foreign subsidiaries are to be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The amendments that are related to franchise taxes that are partially based on income are to be applied on either a retrospective basis for all periods presented or a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. All other amendments under this ASU are to be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

Recently Adopted Accounting Standards
In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The Company adopted this guidance as of July 1, 2020 on a prospective basis, and the adoption did not have a material impact on the Company’s consolidated financial statements at the time of adoption. The impairment identified in the third quarter of fiscal year 2021 was calculated in accordance with this guidance. The future impact of this new standard will depend on the specific facts and circumstances of future impairments that may occur.
v3.21.1
BUSINESS ACQUIRED
9 Months Ended
Mar. 31, 2021
Business Combinations [Abstract]  
BUSINESS ACQUIRED BUSINESS ACQUIRED
Saudi Joint Venture Acquisition

On July 9, 2020, the Company increased its investment in each of the two entities comprising its joint venture in the Kingdom of Saudi Arabia (Saudi joint venture). The joint venture offers customers in the Gulf region a range of cleaning and disinfecting products. The Company had previously accounted for its 30 percent investment of $27 as of June 30, 2020, under the equity method of accounting. Subsequent to the closing of this transaction, the Company’s total ownership interest in each of the entities increased to 51 percent. The Company has consolidated this joint venture into the Company’s consolidated financial statements from the date of acquisition and reflects operations within the International reportable segment. The equity and income attributable to the other joint venture owners is recorded and presented as noncontrolling interests.

The total purchase consideration of $111 consisted of $100 cash paid, which was sourced from operations, and $11 from the net effective settlement of preexisting arrangements between the Company and the joint venture. The assets and liabilities of the joint venture were recorded at their respective estimated fair value as of the acquisition date using generally accepted accounting principles for business combinations. The excess of the purchase price over the fair value of the net identifiable assets acquired has been allocated to goodwill in the International reportable segment in the amount of $208. The goodwill is primarily attributable to the synergies expected to arise after the acquisition and reflects the value of further growth anticipated in the Gulf region. None of the goodwill is deductible for tax purposes.

As a result of this transaction, the carrying value of the Company’s previously held equity investment was remeasured to fair value, and resulted in an $85 non-recurring, non-cash gain recorded in Other (income) expense, net in the condensed consolidated statement of earnings and adjusted in Other operating activities in the condensed consolidated statement of cash flows for the first quarter of fiscal year 2021. The fair values of the noncontrolling interests and previously held equity interest were determined using a discounted cash flow (DCF) method under the income approach. Under this approach, the Company estimates future cash flows and discounts these cash flows at a rate of return that reflects the entities’ relative risk.
 
The purchase price allocation was finalized during the second quarter of fiscal year 2021. The following table summarizes the final purchase price allocation for the fair value of the joint venture’s assets acquired and liabilities assumed and the related deferred income taxes as of the acquisition date. The fair value of the assets acquired and liabilities assumed reflects the final insignificant measurement period adjustments related to goodwill, deferred income taxes and income taxes payable. The definite-lived intangibles acquired primarily represent the Company reacquiring previously licensed trademarks and customer relationships. The weighted-average estimated useful life of intangible assets subject to amortization is 9 years.

Joint Venture
Goodwill$208 
Reacquired rights (included in Other intangible assets, net)138 
Property, plant and equipment46 
Customer relationships (included in Other intangible assets, net)10 
Working capital, net (includes cash acquired of $26)
34 
Noncurrent liabilities, net(5)
Deferred income taxes(19)
Total fair value of net assets412 
Less: Fair value of noncontrolling interests(198)
Less: Fair value of previously held equity interest(103)
Total purchase consideration$111 

Included in the Company’s results for the three and nine months ended March 31, 2021 was $19 and $65, respectively, of net sales from the joint venture. Pro forma results reflecting this transaction were not presented because it is not significant to the Company’s consolidated financial results.
v3.21.1
INVENTORIES, NET
9 Months Ended
Mar. 31, 2021
Inventory Disclosure [Abstract]  
INVENTORIES, NET INVENTORIES, NET
Inventories, net, consisted of the following as of:
3/31/20216/30/2020
Finished goods$522 $340 
Raw materials and packaging188 140 
Work in process10 
LIFO allowances(32)(33)
Total$688 $454 
v3.21.1
GOODWILL, TRADEMARK AND OTHER ASSETS IMPAIRMENTS
9 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
GOODWILL, TRADEMARKS AND OTHER INTANGIBLE ASSETS GOODWILL, TRADEMARK AND OTHER ASSETS IMPAIRMENTS
During the third quarter of fiscal 2021, as a result of lower than expected actual and projected net sales growth and operating performance for the Vitamins, Minerals and Supplements (VMS) strategic business unit (SBU), a strategic review was initiated by management that resulted in updated financial and operational plans. These events were considered a triggering event requiring interim impairment assessments to be performed on the VMS reporting unit, indefinite-lived trademarks and other assets. Based on the outcome of these assessments, the following pre-tax impairment charges were recorded:
Impairment Charge
Goodwill$228 
Trademarks, net86 
Other intangible assets, net14 
Property, plant and equipment, net
Total$329 
In connection with recognizing these impairment charges, the Company recognized tax benefits related to the impairments of $62 due to the partial tax deductibility of these charges.

The impairment charges are a result of a higher level of competitive activity than originally assumed, accelerated declines in the channel where the business is over-developed, and higher than anticipated investments to grow the business, which have adversely affected the assumptions used to determine the fair value of the respective assets held by the VMS reporting unit for growth and the estimates of expenses necessary to achieve that growth. These impairment charges are based on the Company’s current estimates regarding the future financial performance of the VMS SBU and macroeconomic factors.

To determine the fair value of the VMS reporting unit, the Company used a DCF method under the income approach. Under this approach, the Company estimated the future cash flows of the VMS reporting unit and discounted these cash flows at a rate of return that reflects its relative risk. The other key estimates and factors used in the DCF method include, but are not limited to, net sales and expense growth rates, and a terminal growth rate.

Changes in the carrying amount of Goodwill as of March 31, 2021 from June 30, 2020, were as follows:
Goodwill
Health and WellnessHouseholdLifestyleInternationalTotal
Balance as of June 30, 2020$857 $85 $244 $391 $1,577 
Acquisitions— — — 212 212 
Translation adjustments and other— — — 
Balance as of September 30, 2020857 85 244 607 1,793 
Translation adjustments and other (1)
— — — 10 10 
Balance as of December 31, 2020857 85 244 617 1,803 
Goodwill impairment(228)— — — (228)
Translation adjustments and other— — — (1)(1)
Balance as of March 31, 2021$629 $85 $244 $616 $1,574 
(1) Includes $(4) purchase price allocation adjustment related to the Saudi joint venture acquisition. Refer to Note 2 of the Notes to Condensed Consolidated Financial Statements.
To determine the estimated fair values of the VMS related indefinite-lived trademarks, which were included within the Health and Wellness reportable segment, the Company used the income approach. This approach requires significant judgments in determining the royalty rates and the assets’ estimated cash flows as well as the appropriate discount rates applied to those cash flows to determine fair value. In addition, the useful lives of the impaired trademarks, with a remaining net carrying value of $13 as of March 31, 2021, were changed from indefinite to definite beginning on April 1, 2021, which reflects the remaining expected useful lives of the trademarks based on the most recent financial and operational plans. The weighted-average estimated useful life of these trademarks is 16 years.

The following table summarizes the carrying amount of trademarks and other intangible assets as of March 31, 2021 and as of June 30, 2020: 
As of March 31, 2021As of June 30, 2020
Gross carrying amountAccumulated amortization / ImpairmentsNet carrying amountGross carrying amountAccumulated amortization / ImpairmentsNet carrying amount
Trademarks not subject to amortization$769 $86 $683 $766 $— $766 
Trademarks subject to amortization47 36 11 47 28 19 
Other intangible assets583 337 246 424 315 109 
Total$1,399 $459 $940 $1,237 $343 $894 
Amortization expense relating to the Company’s intangible assets was $8 and $23 for the three and nine months ended March 31, 2021, respectively, and $3 and $10 for the three and nine months ended March 31, 2020, respectively. Estimated amortization expense for these intangible assets is $8, $32, $30, $29 and $28 for the remainder of fiscal year 2021 and fiscal years 2022, 2023, 2024 and 2025, respectively.
v3.21.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
9 Months Ended
Mar. 31, 2021
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS
Financial Risk Management and Derivative Instruments

The Company is exposed to certain commodity, foreign currency and interest rate risks related to its ongoing business operations and uses derivative instruments to mitigate its exposure to these risks.

Commodity Price Risk Management

The Company may use commodity exchange traded futures and over-the-counter swap contracts, which are generally no longer than 2 years, to fix the price of a portion of its forecasted raw material requirements. Commodity purchase contracts are measured at fair value using market quotations obtained from the Chicago Board of Trade commodity futures exchange and commodity derivative dealers.

As of March 31, 2021, the notional amount of commodity derivatives was $24, of which $15 related to soybean oil futures used for the Food products business and $9 related to jet fuel swaps used for the Grilling business. As of June 30, 2020, the notional amount of commodity derivatives was $27, of which $14 related to soybean oil futures and $13 related to jet fuel swaps.

Foreign Currency Risk Management

The Company may also enter into certain over-the-counter derivative contracts to manage a portion of the Company’s forecasted foreign currency exposure associated with the purchase of inventory. These foreign currency contracts generally have durations of no longer than 2 years. The foreign exchange contracts are measured at fair value using information quoted by foreign exchange dealers.

The notional amounts of outstanding foreign currency forward contracts used by the Company’s subsidiaries to hedge forecasted purchases of inventory were $68 and $70, respectively, as of March 31, 2021 and June 30, 2020.
Interest Rate Risk Management

The Company may enter into over-the-counter interest rate forward or swap contracts to fix a portion of the benchmark interest rate prior to the anticipated issuance of fixed rate debt or to manage the Company’s level of fixed and floating rate debt. These interest rate forward or swap contracts historically have had durations of less than 3 years. The interest rate contracts are measured at fair value using information quoted by U.S. government bond and interest rate derivative dealers.

The notional amounts of outstanding interest rate contracts used by the Company were $300 and $225, respectively, as of March 31, 2021 and June 30, 2020. These contracts represent forward starting interest rate swap contracts with a maturity date of September 2022 to manage the exposure to interest rate volatility associated with future interest payments on a forecasted debt issuance.

Commodity, Foreign Exchange and Interest Rate Derivatives

The Company designates its commodity forward and futures contracts for forecasted purchases of raw materials, foreign currency forward contracts for forecasted purchases of inventory and interest rate forward contracts for forecasted interest payments as cash flow hedges.

The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:

Gains (losses) recognized in Other comprehensive (loss) income
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Commodity purchase derivative contracts$$(11)$12 $(8)
Foreign exchange derivative contracts(1)
Interest rate derivative contracts26 — 36 — 
Total$33 $(9)$47 $(6)

Location of Gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Commodity purchase derivative contractsCost of products sold$— $— $(2)$(1)
Foreign exchange derivative contractsCost of products sold— — — — 
Interest rate derivative contractsInterest expense(2)(2)(5)(5)
Total$(2)$(2)$(7)$(6)

The estimated amount of the existing net gain (loss) in Accumulated other comprehensive net (loss) income as of March 31, 2021, that is expected to be reclassified into Net earnings (losses) within the next twelve months is $2.
Counterparty Risk Management and Derivative Contract Requirements

The Company utilizes a variety of financial institutions as counterparties for over-the-counter derivative instruments. The Company enters into agreements governing the use of over-the-counter derivative instruments and sets internal limits on the aggregate over-the-counter derivative instrument positions held with each counterparty. Certain terms of these agreements require the Company or the counterparty to post collateral when the fair value of the derivative instruments exceeds contractually-defined counterparty liability position limits. Of the over-the-counter derivative instruments in liability positions held as of March 31, 2021 and June 30, 2020, $1 and $3, respectively, contained such terms. As of March 31, 2021 and June 30, 2020, neither the Company nor any counterparty was required to post any collateral, as no counterparty liability position limits were exceeded.

Certain terms of the agreements governing the Company’s over-the-counter derivative instruments require the credit ratings, as assigned by Standard & Poor’s and Moody’s to the Company and its counterparties, to remain at a level equal to or better than the minimum of an investment grade credit rating. If the Company’s credit ratings were to fall below investment grade, the counterparties to the derivative instruments could request full collateralization on derivative instruments in net liability positions. As of both March 31, 2021 and June 30, 2020, the Company and each of its counterparties had been assigned investment grade ratings by both Standard & Poor’s and Moody’s.

Certain of the Company’s exchange-traded futures contracts used for commodity price risk management include requirements for the Company to post collateral in the form of a cash margin account held by the Company’s broker for trades conducted on that exchange. As of March 31, 2021 and June 30, 2020, the Company maintained cash margin balances related to exchange-traded futures contracts of $0 and $2, respectively, which are classified as Prepaid expenses and other current assets on the condensed consolidated balance sheets.

Trust Assets

The Company has held interests in mutual funds and cash equivalents as part of the trust assets related to its nonqualified deferred compensation plans. The participants in the nonqualified deferred compensation plans, who are the Company’s current and former employees, may select among certain mutual funds in which to invest their compensation deferrals in accordance with the terms of the plans and within the confines of the trusts, which hold the marketable securities. The trusts represent variable interest entities for which the Company is considered the primary beneficiary, and, therefore, trust assets are consolidated and included in Other assets in the condensed consolidated balance sheets. The interests in mutual funds are measured at fair value using quoted market prices. The Company has designated these marketable securities as trading investments.

Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of March 31, 2021 and June 30, 2020, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
All of the Company’s derivative instruments qualify for hedge accounting. The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 3/31/20216/30/2020
Balance Sheet
Classification
Fair Value
Hierarchy
Level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Commodity purchase futures contractsOther current assets1$$$— $— 
Commodity purchase swaps contractsOther current assets2— — 
Commodity purchase swaps contractsOther assets2— — — — 
Interest rate forward contractsOther assets237 37 
 $42 $42 $$
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$— $— $$
Commodity purchase swaps contractsAccounts payable and accrued liabilities2— — 
Foreign exchange forward contractAccounts payable and accrued liabilities2
$$$$

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 3/31/20216/30/2020
Balance Sheet
Classification
Fair Value
Hierarchy
Level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Investments, including money market funds
Cash and cash
equivalents (1)
1$213 $213 $584 $584 
Time deposits
Cash and cash
equivalents (1)
2146 146 165 165 
Trust assets for nonqualified deferred compensation plansOther assets1131 131 100 100 
 $490 $490 $849 $849 
Liabilities
Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt (2)
22,783 2,944 2,780 3,051 
$2,783 $2,944 $2,780 $3,051 
____________________

(1)Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.

Furthermore, impairment charges of $329 were recorded during the third quarter of fiscal 2021, of which $228, $86, and $15 related to the goodwill of the VMS reporting unit, certain indefinite-lived trademarks and other assets, respectively. These adjustments were included as non-cash charges in the condensed consolidated statement of earnings. The non-recurring fair values utilized included unobservable Level 3 inputs based on management’s best estimates and assumptions. For additional information, refer to Note 4 of the Notes to Condensed Consolidated Financial Statements
v3.21.1
INCOME TAXES
9 Months Ended
Mar. 31, 2021
Income Tax Disclosure [Abstract]  
INCOME TAXES INCOME TAXESIn determining its quarterly provision for income taxes, the Company uses an estimated annual effective tax rate, which is based on expected annual income, statutory tax rates and tax planning opportunities available in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter in which they occur and can be a source of variability in the effective tax rates from quarter to quarter. The effective tax rate on earnings (losses) was (1.4)% and 22.5% for the current three and nine months ended March 31, 2021, respectively, and 18.9% and 20.4% for the prior three and nine months ended March 31, 2020, respectively. The substantially lower tax rate on loss before income taxes in the current three month period and higher tax rate on earnings before income taxes in the current nine month period were driven by the partial non-deductibility of impaired VMS goodwill.
v3.21.1
NET EARNINGS (LOSSES) PER SHARE (EPS)
9 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
NET EARNINGS (LOSSES) PER SHARE (EPS) NET EARNINGS (LOSSES) PER SHARE (EPS)
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Basic125,610125,661126,057125,641
Dilutive effect of stock options and other1,6671,9731,595
Diluted125,610127,328128,030127,236
Antidilutive stock options and other4,826— 428 

Basic net earnings (losses) per share and Diluted net earnings (losses) per share are calculated on Net earnings (losses) attributable to Clorox.

Since the Company generated net losses attributable to Clorox for the three months ended March 31, 2021, there was no dilutive effect of stock options and other instruments because their impact would be antidilutive.
v3.21.1
COMPREHENSIVE INCOME (LOSS)
9 Months Ended
Mar. 31, 2021
Stockholders' Equity Note [Abstract]  
COMPREHENSIVE INCOME (LOSS) COMPREHENSIVE INCOME (LOSS)
The following table provides a summary of Comprehensive income (loss) for the periods indicated:
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Net earnings (losses)$(59)$241 $619 $629 
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments(7)(51)40 (58)
Net unrealized gains (losses) on derivatives27 (5)42 
Pension and postretirement benefit adjustments
Total other comprehensive (loss) income, net of tax22 (55)87 (54)
Comprehensive income (loss)(37)186 706 575 
Less: Total comprehensive income attributable to noncontrolling interests— — 
Total comprehensive income (loss) attributable to Clorox$(39)$186 $700 $575 
v3.21.1
STOCKHOLDERS' EQUITY
9 Months Ended
Mar. 31, 2021
Equity [Abstract]  
STOCKHOLDERS' EQUITY STOCKHOLDERS EQUITY
Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three Months Ended March 31
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income
Non-controlling interests
Total Stockholders Equity
AmountShares AmountShares
Balance as of December 31, 2019$159 158,741 $1,062 $3,292 $(3,357)(33,717)$(601)$— $555 
Net earnings— — — 241 — — — — 241 
Other comprehensive (loss) income— — — — — — (55)— (55)
Dividends to Clorox stockholders ($1.06 per share declared)
— — — (135)— — — — (135)
Stock-based compensation— — 18 — — — — — 18 
Other employee stock plan activities— — 31 — 70 1,083 — — 101 
Treasury stock purchased— — — — (30)(184)— — (30)
Balance as of March 31, 2020$159 158,741 $1,111 $3,398 $(3,317)(32,818)$(656)$— $695 
Balance as of December 31, 2020$131 130,741 $1,176 $1,302 $(850)(5,017)$(575)$196 $1,380 
Net earnings (losses)— — — (61)— — — (59)
Other comprehensive (loss) income— — — — — — 22 — 22 
Dividends to Clorox stockholders ($1.11 per share declared)
— — — (139)— — — — (139)
Dividends to non-controlling interests— — — — — — — (3)(3)
Stock-based compensation— — 17 — — — — — 17 
Other employee stock plan activities— — (3)(16)44 283 — — 25 
Treasury stock purchased— — — — (305)(1,648)— — (305)
Balance as of March 31, 2021$131 130,741 $1,190 $1,086 $(1,111)(6,382)$(553)$195 $938 
Nine Months Ended March 31
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income
Non-controlling interests
Total Stockholders Equity
AmountSharesAmountShares
Balance as of June 30, 2019$159 158,741 $1,046 $3,150 $(3,194)(33,055)$(602)$— $559 
Cumulative effect of accounting changes, net of tax (1)
— — — 22 — — — — 22 
Net earnings— — — 629 — — — — 629 
Other comprehensive (loss) income— — — — — — (54)— (54)
Dividends to Clorox stockholders ($3.18 per share declared)
— — — (402)— — — — (402)
Stock-based compensation— — 37 — — — — — 37 
Other employee stock plan activities— — 28 (1)96 1,661 — — 123 
Treasury stock purchased— — — — (219)(1,424)— — (219)
Balance as of March 31, 2020$159 158,741 $1,111 $3,398 $(3,317)(32,818)$(656)$— $695 
Balance as of June 30, 2020$159 158,741 $1,137 $3,567 $(3,315)(32,543)$(640)$— $908 
Net earnings— — — 613 — — — 619 
Other comprehensive (loss) income— — — — — — 87 — 87 
Dividends to Clorox stockholders ($3.33 per share declared)
— — — (421)— — — — (421)
Dividends to noncontrolling interests— — — — — — — (9)(9)
Business combinations including purchase accounting adjustments— — — — — — — 198 198 
Stock-based compensation— — 52 — — — — — 52 
Other employee stock plan activities— — (33)141 1,233 — — 109 
Treasury stock purchased— — — — (605)(3,072)— — (605)
Treasury stock retirement (28)(28,000)— (2,640)2,668 28,000 — — — 
Balance as of March 31, 2021$131 130,741 $1,190 $1,086 $(1,111)(6,382)$(553)$195 $938 
(1) As a result of adopting ASU No. 2016-02, “Leases (Topic 842),” on July 1, 2019, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2020 opening balance of Retained earnings.
On November 18, 2020 the Company retired 28 million shares of its treasury stock. These shares are now authorized but unissued. There was no effect on the Company’s overall equity position as a result of the retirement.

The Company has two stock repurchase programs: an open-market purchase program with an authorized aggregate purchase amount of up to $2,000, which has no expiration date, and a program to offset the anticipated impact of dilution related to stock-based awards (the Evergreen Program), which has no authorization limit on the dollar amount and no expiration date.

Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
AmountShares
(in thousands)
AmountShares
(in thousands)
AmountShares
(in thousands)
AmountShares
(in thousands)
Open-market purchase program$200 1,088 $— — $200 1,088 $85 577 
Evergreen Program105 560 30 184 405 1,984 134 847 
Total stock repurchases$305 1,648 $30 184 $605 3,072 $219 1,424 
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three Months Ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of December 31, 2019$(421)$(17)$(163)$(601)
Other comprehensive (loss) income before reclassifications(49)(9)— (58)
Amounts reclassified from Accumulated other comprehensive net (loss) income— 
Income tax benefit (expense)(2)(1)(1)
Net current period other comprehensive (loss) income(51)(5)(55)
Balance as of March 31, 2020$(472)$(22)$(162)$(656)
Balance as of December 31, 2020$(403)$(3)$(169)$(575)
Other comprehensive (loss) income before reclassifications(6)33 — 27 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 
Income tax benefit (expense), and other(1)(8)(1)(10)
Net current period other comprehensive (loss) income(7)27 22 
Balance as of March 31, 2021$(410)$24 $(167)$(553)
Nine Months Ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of June 30, 2019$(414)$(23)$(165)$(602)
Other comprehensive (loss) income before reclassifications(55)(6)— (61)
Amounts reclassified from Accumulated other comprehensive net (loss) income— 11 
Income tax benefit (expense)(3)(2)(4)
Net current period other comprehensive (loss) income(58)(54)
Balance as of March 31, 2020$(472)$(22)$(162)$(656)
Balance as of June 30, 2020$(450)$(18)$(172)$(640)
Other comprehensive (loss) income before reclassifications38 47 — 85 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 14 
Income tax benefit (expense), and other(12)(2)(12)
Net current period other comprehensive (loss) income40 42 87 
Balance as of March 31, 2021$(410)$24 $(167)$(553)

Included in foreign currency translation adjustments are re-measurement losses on long-term intercompany loans where settlement is not planned or anticipated in the foreseeable future. There were no amounts associated with these loans reclassified from Accumulated other comprehensive net (loss) income for the periods presented.
v3.21.1
EMPLOYEE BENEFIT PLANS
9 Months Ended
Mar. 31, 2021
Retirement Benefits [Abstract]  
EMPLOYEE BENEFIT PLANS EMPLOYEE BENEFIT PLANS
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Service cost$— $— $— $— 
Interest cost11 15 
Expected return on plan assets (1)
(4)(5)(11)(14)
Amortization of unrecognized items
Total$$$$
(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2021 net periodic benefit cost is 3.1%.
The net periodic benefit cost for the Company’s retirement health care plans was $0 for both the three months ended March 31, 2021 and 2020, and $(1) for both the nine months ended March 31, 2021 and 2020.
During the three months ended March 31, 2021 and 2020, the Company made $6 and $7 in contributions to its domestic retirement income plans, respectively. During the nine months ended March 31, 2021 and 2020, the Company made $10 in contributions to its domestic retirement income plans.
Net periodic benefit costs are reflected in Other (income) expense, net.
v3.21.1
OTHER CONTINGENCIES AND GUARANTEES
9 Months Ended
Mar. 31, 2021
OTHER CONTINGENCIES AND GUARANTEES [Abstract]  
OTHER CONTINGENCIES AND GUARANTEES OTHER CONTINGENCIES AND GUARANTEES
Contingencies
The Company is involved in certain environmental matters, including response actions at various locations. The Company had recorded liabilities totaling $27 and $28 as of March 31, 2021 and June 30, 2020, respectively, for its share of aggregate future remediation costs related to these matters.
One matter, which accounted for $14 of the recorded liability as of March 31, 2021 and June 30, 2020, relates to environmental costs associated with one of the Company’s former operations at a site located in Alameda County, California. In November 2016, at the request of regulators and with the assistance of environmental consultants, the Company submitted a Feasibility Study that evaluated various options for managing the site and included estimates of the related costs. As a result, the Company recorded in Other (income) expense, net an undiscounted liability for costs estimated to be incurred over a 30-year period, based on the option recommended in the Feasibility Study. However, as a result of ongoing discussions with regulators, in June 2017, the Company increased its recorded liability to $14, which reflects anticipated costs to implement additional remediation measures at this site. While the Company believes its latest estimate is reasonable, regulators could require the Company to implement one of the other options evaluated in the Feasibility Study, with estimated undiscounted costs of up to $28 over an estimated 30-year period, or require the Company to take other actions and incur costs not included in the study.
Another matter in Dickinson County, Michigan, at the site of one of the Company’s former operations for which the Company is jointly and severally liable, accounted for $10 of the recorded liability, as of March 31, 2021 and June 30, 2020. This amount reflects the Company’s agreement to be liable for 24.3% of the aggregate remediation and associated costs for this matter pursuant to a cost-sharing arrangement with a third party. If the third party is unable to pay its share of the response and remediation obligations, the Company may be responsible for such obligations. With the assistance of environmental consultants, the Company maintains an undiscounted liability representing its current best estimate of its share of the capital expenditures, maintenance and other costs that may be incurred over an estimated 30-year remediation period. Although it is reasonably possible that the Company’s exposure may exceed the amount recorded for the Dickinson County matter, any amount of such additional exposures, or range of exposures, is not estimable at this time. The Company’s estimated losses related to these matters are sensitive to a variety of uncertain factors, including the efficacy of any remediation efforts, changes in any remediation requirements, and the future availability of alternative clean-up technologies.
The Company is subject to various legal proceedings, claims and other loss contingencies, including, without limitation, loss contingencies relating to contractual arrangements, product liability, patents and trademarks, advertising, labor and employment, environmental, health and safety and other matters. With respect to these proceedings, claims and other loss contingencies, while considerable uncertainty exists, in the opinion of management at this time, the ultimate disposition of these matters, to the extent not previously provided for, will not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
Guarantees
In conjunction with divestitures and other transactions, the Company may provide typical indemnifications (e.g., indemnifications for representations and warranties and retention of previously existing environmental, tax and employee liabilities) that have terms that vary in duration and in the potential amount of the total obligation and, in many circumstances, are not explicitly defined. The Company has not made, nor does it believe that it is probable that it will make, any material payments relating to its indemnifications, and believes that any reasonably possible payments would not have a material adverse effect, either individually or in the aggregate, on the Company’s condensed consolidated financial statements taken as a whole.
The Company had not recorded any material liabilities on the aforementioned guarantees as of March 31, 2021 and June 30, 2020.
As of March 31, 2021, the Company was party to a letter of credit of $11, related to one of its insurance carriers, of which $0 had been drawn upon.
v3.21.1
SEGMENT RESULTS
9 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
SEGMENT RESULTS SEGMENT RESULTS
The Company operates through SBUs that are aggregated into four reportable segments based on the economics and nature of the products sold: Health and Wellness, Household, Lifestyle and International. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated Net sales and Earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.
Net sales
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Health and Wellness$680 $736 $2,310 $1,944 
Household510 480 1,421 1,183 
Lifestyle293 294 928 856 
International298 273 880 755 
Corporate— — — — 
Total$1,781 $1,783 $5,539 $4,738 
Earnings (losses) before income taxes
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Health and Wellness (1)
$(183)$210 $315 $514 
Household97 114 266 190 
Lifestyle68 80 259 242 
International30 36 184 106 
Corporate(71)(143)(225)(262)
Total$(59)$297 $799 $790 
(1) The earnings (losses) before income taxes for the Health and Wellness segment include a $329 non-cash goodwill, trademark and other asset impairment charge for the VMS SBU for the three and nine months ended March 31, 2021.

All intersegment sales are eliminated and are not included in the Company’s reportable segments’ net sales.
Net sales to the Company’s largest customer, Wal-Mart Stores, Inc. and its affiliates, as a percentage of consolidated net sales, were 24% for each of the three and nine months ended March 31, 2021, respectively, and 25% for each of the three and nine months ended March 31, 2020, respectively.
The following table provides Net sales as a percentage of the Company’s consolidated net sales for the Company’s SBUs and for the periods indicated:
Net sales
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Cleaning29 %32 %30 %31 %
Professional Products%%%%
Vitamins, Minerals and Supplements%%%%
Health and Wellness38 %42 %41 %41 %
Bags and Wraps11 %11 %11 %12 %
Cat Litter%%%%
Grilling11 %%%%
Household29 %27 %26 %25 %
Food Products10 %%%%
Natural Personal Care%%%%
Water Filtration%%%%
Lifestyle16 %16 %17 %18 %
International17 %15 %16 %16 %
Total100 %100 %100 %100 %
v3.21.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
9 Months Ended
Mar. 31, 2021
Accounting Policies [Abstract]  
Basis of Presentation
Basis of Presentation

The unaudited interim condensed consolidated financial statements for the three and nine months ended March 31, 2021 and 2020, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals) necessary for a fair presentation of the consolidated results of operations, financial position and cash flows of The Clorox Company and its controlled subsidiaries (the Company) for the periods presented. However, the financial results for interim periods are not necessarily indicative of the results that may be expected for a full fiscal year or for any other future period.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (U.S. GAAP) have been omitted or condensed pursuant to the rules and regulations of the U.S. Securities and Exchange Commission (SEC). The information in this report should be read in conjunction with the Company’s Annual Report on Form 10-K filed with the SEC for the fiscal year ended June 30, 2020, which includes a complete set of footnote disclosures, including the Company’s significant accounting policies.
Recently Issued Accounting Standards
Recently Issued Accounting Standards

Recently Issued Accounting Standards Not Yet Adopted

In December 2019, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) No. 2019-12, “Income Taxes (ASC 740): Simplifying the Accounting for Income Taxes,” which improves consistency in the application of accounting for income taxes by removing certain exceptions to the general principles in ASC 740 and by clarifying and amending existing guidance. The standard will be effective for the Company beginning in the first quarter of fiscal year 2022, with early adoption permitted. The amendments that are related to changes in ownership of foreign equity method investments or foreign subsidiaries are to be applied on a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. The amendments that are related to franchise taxes that are partially based on income are to be applied on either a retrospective basis for all periods presented or a modified retrospective basis through a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. All other amendments under this ASU are to be applied on a prospective basis. The Company is currently evaluating the impact that the adoption of this guidance will have on its consolidated financial statements.

Recently Adopted Accounting Standards
In January 2017, the FASB issued ASU No. 2017-04, “Intangibles-Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment,” which eliminates the requirement to calculate the implied fair value of goodwill to measure a goodwill impairment charge. The Company adopted this guidance as of July 1, 2020 on a prospective basis, and the adoption did not have a material impact on the Company’s consolidated financial statements at the time of adoption. The impairment identified in the third quarter of fiscal year 2021 was calculated in accordance with this guidance. The future impact of this new standard will depend on the specific facts and circumstances of future impairments that may occur.
Fair Value Measurement
Fair Value Measurements

Financial assets and liabilities measured at fair value on a recurring basis in the condensed consolidated balance sheets are required to be classified and disclosed in one of the following three categories of the fair value hierarchy:

Level 1: Quoted market prices in active markets for identical assets or liabilities.
Level 2: Observable market-based inputs or unobservable inputs that are corroborated by market data.
Level 3: Unobservable inputs reflecting the reporting entity’s own assumptions.

As of March 31, 2021 and June 30, 2020, the Company’s financial assets and liabilities that were measured at fair value on a recurring basis included derivative financial instruments, which were classified as either Level 1 or Level 2, and trust assets to fund the Company’s nonqualified deferred compensation plans, which were classified as Level 1.
Segment Results
The Company operates through SBUs that are aggregated into four reportable segments based on the economics and nature of the products sold: Health and Wellness, Household, Lifestyle and International. Prior periods presented have been recast to reflect the reportable segment changes effective in the fourth quarter of fiscal year 2020.
Certain non-allocated administrative costs, interest income, interest expense and various other non-operating income and expenses are reflected in Corporate. Corporate assets include cash and cash equivalents, prepaid expenses and other current assets, property and equipment, operating lease right-of-use assets, other long-term assets and deferred taxes.
v3.21.1
BUSINESS ACQUIRED (Tables)
9 Months Ended
Mar. 31, 2021
Business Combinations [Abstract]  
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed The following table summarizes the final purchase price allocation for the fair value of the joint venture’s assets acquired and liabilities assumed and the related deferred income taxes as of the acquisition date. The fair value of the assets acquired and liabilities assumed reflects the final insignificant measurement period adjustments related to goodwill, deferred income taxes and income taxes payable. The definite-lived intangibles acquired primarily represent the Company reacquiring previously licensed trademarks and customer relationships. The weighted-average estimated useful life of intangible assets subject to amortization is 9 years.
Joint Venture
Goodwill$208 
Reacquired rights (included in Other intangible assets, net)138 
Property, plant and equipment46 
Customer relationships (included in Other intangible assets, net)10 
Working capital, net (includes cash acquired of $26)
34 
Noncurrent liabilities, net(5)
Deferred income taxes(19)
Total fair value of net assets412 
Less: Fair value of noncontrolling interests(198)
Less: Fair value of previously held equity interest(103)
Total purchase consideration$111 
v3.21.1
INVENTORIES, NET (Tables)
9 Months Ended
Mar. 31, 2021
Inventory Disclosure [Abstract]  
Schedule of Inventories, Net
Inventories, net, consisted of the following as of:
3/31/20216/30/2020
Finished goods$522 $340 
Raw materials and packaging188 140 
Work in process10 
LIFO allowances(32)(33)
Total$688 $454 
v3.21.1
GOODWILL, TRADEMARK AND OTHER ASSETS IMPAIRMENTS (Tables)
9 Months Ended
Mar. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Schedule of Impaired Intangible Assets Based on the outcome of these assessments, the following pre-tax impairment charges were recorded:
Impairment Charge
Goodwill$228 
Trademarks, net86 
Other intangible assets, net14 
Property, plant and equipment, net
Total$329 
Schedule of Goodwill
Changes in the carrying amount of Goodwill as of March 31, 2021 from June 30, 2020, were as follows:
Goodwill
Health and WellnessHouseholdLifestyleInternationalTotal
Balance as of June 30, 2020$857 $85 $244 $391 $1,577 
Acquisitions— — — 212 212 
Translation adjustments and other— — — 
Balance as of September 30, 2020857 85 244 607 1,793 
Translation adjustments and other (1)
— — — 10 10 
Balance as of December 31, 2020857 85 244 617 1,803 
Goodwill impairment(228)— — — (228)
Translation adjustments and other— — — (1)(1)
Balance as of March 31, 2021$629 $85 $244 $616 $1,574 
(1) Includes $(4) purchase price allocation adjustment related to the Saudi joint venture acquisition. Refer to Note 2 of the Notes to Condensed Consolidated Financial Statements.
Schedule of Acquired Indefinite-lived Intangible Assets by Major Class
The following table summarizes the carrying amount of trademarks and other intangible assets as of March 31, 2021 and as of June 30, 2020: 
As of March 31, 2021As of June 30, 2020
Gross carrying amountAccumulated amortization / ImpairmentsNet carrying amountGross carrying amountAccumulated amortization / ImpairmentsNet carrying amount
Trademarks not subject to amortization$769 $86 $683 $766 $— $766 
Trademarks subject to amortization47 36 11 47 28 19 
Other intangible assets583 337 246 424 315 109 
Total$1,399 $459 $940 $1,237 $343 $894 
Schedule of Finite-Lived Intangible Assets
The following table summarizes the carrying amount of trademarks and other intangible assets as of March 31, 2021 and as of June 30, 2020: 
As of March 31, 2021As of June 30, 2020
Gross carrying amountAccumulated amortization / ImpairmentsNet carrying amountGross carrying amountAccumulated amortization / ImpairmentsNet carrying amount
Trademarks not subject to amortization$769 $86 $683 $766 $— $766 
Trademarks subject to amortization47 36 11 47 28 19 
Other intangible assets583 337 246 424 315 109 
Total$1,399 $459 $940 $1,237 $343 $894 
v3.21.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)
9 Months Ended
Mar. 31, 2021
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS [Abstract]  
Effects of Derivative Instruments Designated as Hedging Instruments on OCI
The effects of derivative instruments designated as hedging instruments on Other comprehensive (loss) income and Net earnings were as follows:

Gains (losses) recognized in Other comprehensive (loss) income
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Commodity purchase derivative contracts$$(11)$12 $(8)
Foreign exchange derivative contracts(1)
Interest rate derivative contracts26 — 36 — 
Total$33 $(9)$47 $(6)
Effects of Derivative Instruments Designated as Hedging Instruments on Net Earnings
Location of Gains (losses) reclassified from Accumulated other comprehensive net (loss) income into Net earningsGains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Commodity purchase derivative contractsCost of products sold$— $— $(2)$(1)
Foreign exchange derivative contractsCost of products sold— — — — 
Interest rate derivative contractsInterest expense(2)(2)(5)(5)
Total$(2)$(2)$(7)$(6)
Schedule of Assets and Liabilities for Fair Value Disclosure The following table provides information about the balance sheet classification and the fair values of the Company’s derivative instruments:
 3/31/20216/30/2020
Balance Sheet
Classification
Fair Value
Hierarchy
Level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Commodity purchase futures contractsOther current assets1$$$— $— 
Commodity purchase swaps contractsOther current assets2— — 
Commodity purchase swaps contractsOther assets2— — — — 
Interest rate forward contractsOther assets237 37 
 $42 $42 $$
Liabilities
Commodity purchase futures contractsAccounts payable and accrued liabilities1$— $— $$
Commodity purchase swaps contractsAccounts payable and accrued liabilities2— — 
Foreign exchange forward contractAccounts payable and accrued liabilities2
$$$$

The following table provides information about the balance sheet classification and the fair values of the Company’s other assets and liabilities for which disclosure of fair value is required:
 3/31/20216/30/2020
Balance Sheet
Classification
Fair Value
Hierarchy
Level
Carrying
Amount
Estimated
Fair
Value
Carrying
Amount
Estimated
Fair
Value
Assets
Investments, including money market funds
Cash and cash
equivalents (1)
1$213 $213 $584 $584 
Time deposits
Cash and cash
equivalents (1)
2146 146 165 165 
Trust assets for nonqualified deferred compensation plansOther assets1131 131 100 100 
 $490 $490 $849 $849 
Liabilities
Current maturities of long-term debt and Long-term debt
Current maturities of long-
term debt and Long-term
debt (2)
22,783 2,944 2,780 3,051 
$2,783 $2,944 $2,780 $3,051 
____________________

(1)Cash and cash equivalents are composed of time deposits and other interest bearing investments, including money market funds with original maturity dates of 90 days or less. Cash and cash equivalents are recorded at cost, which approximates fair value.
(2)Current maturities of long-term debt and Long-term debt are recorded at cost. The fair value of Long-term debt, including current maturities, was determined using secondary market prices quoted by corporate bond dealers, and is classified as Level 2.
v3.21.1
NET EARNINGS (LOSSES) PER SHARE (EPS) (Tables)
9 Months Ended
Mar. 31, 2021
Earnings Per Share [Abstract]  
Schedule of Weighted Average Number of Shares Outstanding and Antidilutive Shares
The following is the reconciliation of the weighted average number of shares outstanding (in thousands) used to calculate basic net EPS to those used to calculate diluted net EPS:
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Basic125,610125,661126,057125,641
Dilutive effect of stock options and other1,6671,9731,595
Diluted125,610127,328128,030127,236
Antidilutive stock options and other4,826— 428 
v3.21.1
COMPREHENSIVE INCOME (LOSS) (Tables)
9 Months Ended
Mar. 31, 2021
Stockholders' Equity Note [Abstract]  
Schedule of Comprehensive Income
The following table provides a summary of Comprehensive income (loss) for the periods indicated:
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Net earnings (losses)$(59)$241 $619 $629 
Other comprehensive (loss) income, net of tax:
Foreign currency translation adjustments(7)(51)40 (58)
Net unrealized gains (losses) on derivatives27 (5)42 
Pension and postretirement benefit adjustments
Total other comprehensive (loss) income, net of tax22 (55)87 (54)
Comprehensive income (loss)(37)186 706 575 
Less: Total comprehensive income attributable to noncontrolling interests— — 
Total comprehensive income (loss) attributable to Clorox$(39)$186 $700 $575 
v3.21.1
STOCKHOLDERS' EQUITY (Tables)
9 Months Ended
Mar. 31, 2021
Equity [Abstract]  
Schedule of Stockholders Equity
Changes in the components of Stockholders’ equity were as follows for the periods indicated:
Three Months Ended March 31
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income
Non-controlling interests
Total Stockholders Equity
AmountShares AmountShares
Balance as of December 31, 2019$159 158,741 $1,062 $3,292 $(3,357)(33,717)$(601)$— $555 
Net earnings— — — 241 — — — — 241 
Other comprehensive (loss) income— — — — — — (55)— (55)
Dividends to Clorox stockholders ($1.06 per share declared)
— — — (135)— — — — (135)
Stock-based compensation— — 18 — — — — — 18 
Other employee stock plan activities— — 31 — 70 1,083 — — 101 
Treasury stock purchased— — — — (30)(184)— — (30)
Balance as of March 31, 2020$159 158,741 $1,111 $3,398 $(3,317)(32,818)$(656)$— $695 
Balance as of December 31, 2020$131 130,741 $1,176 $1,302 $(850)(5,017)$(575)$196 $1,380 
Net earnings (losses)— — — (61)— — — (59)
Other comprehensive (loss) income— — — — — — 22 — 22 
Dividends to Clorox stockholders ($1.11 per share declared)
— — — (139)— — — — (139)
Dividends to non-controlling interests— — — — — — — (3)(3)
Stock-based compensation— — 17 — — — — — 17 
Other employee stock plan activities— — (3)(16)44 283 — — 25 
Treasury stock purchased— — — — (305)(1,648)— — (305)
Balance as of March 31, 2021$131 130,741 $1,190 $1,086 $(1,111)(6,382)$(553)$195 $938 
Nine Months Ended March 31
(Dollars in millions except per share data; shares in thousands)
Common StockAdditional Paid-in CapitalRetained EarningsTreasury StockAccumulated
Other
Comprehensive
Net (Loss) Income
Non-controlling interests
Total Stockholders Equity
AmountSharesAmountShares
Balance as of June 30, 2019$159 158,741 $1,046 $3,150 $(3,194)(33,055)$(602)$— $559 
Cumulative effect of accounting changes, net of tax (1)
— — — 22 — — — — 22 
Net earnings— — — 629 — — — — 629 
Other comprehensive (loss) income— — — — — — (54)— (54)
Dividends to Clorox stockholders ($3.18 per share declared)
— — — (402)— — — — (402)
Stock-based compensation— — 37 — — — — — 37 
Other employee stock plan activities— — 28 (1)96 1,661 — — 123 
Treasury stock purchased— — — — (219)(1,424)— — (219)
Balance as of March 31, 2020$159 158,741 $1,111 $3,398 $(3,317)(32,818)$(656)$— $695 
Balance as of June 30, 2020$159 158,741 $1,137 $3,567 $(3,315)(32,543)$(640)$— $908 
Net earnings— — — 613 — — — 619 
Other comprehensive (loss) income— — — — — — 87 — 87 
Dividends to Clorox stockholders ($3.33 per share declared)
— — — (421)— — — — (421)
Dividends to noncontrolling interests— — — — — — — (9)(9)
Business combinations including purchase accounting adjustments— — — — — — — 198 198 
Stock-based compensation— — 52 — — — — — 52 
Other employee stock plan activities— — (33)141 1,233 — — 109 
Treasury stock purchased— — — — (605)(3,072)— — (605)
Treasury stock retirement (28)(28,000)— (2,640)2,668 28,000 — — — 
Balance as of March 31, 2021$131 130,741 $1,190 $1,086 $(1,111)(6,382)$(553)$195 $938 
(1) As a result of adopting ASU No. 2016-02, “Leases (Topic 842),” on July 1, 2019, the Company recorded a cumulative effect of initially applying the new guidance as an adjustment to the fiscal year 2020 opening balance of Retained earnings.
Schedule of Share Repurchases Under Authorized Programs
Stock repurchases under the two stock repurchase programs were as follows for the periods indicated:
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
AmountShares
(in thousands)
AmountShares
(in thousands)
AmountShares
(in thousands)
AmountShares
(in thousands)
Open-market purchase program$200 1,088 $— — $200 1,088 $85 577 
Evergreen Program105 560 30 184 405 1,984 134 847 
Total stock repurchases$305 1,648 $30 184 $605 3,072 $219 1,424 
Schedule of Changes in Accumulated Other Comprehensive Net (Losses) Income
Changes in Accumulated other comprehensive net (loss) income attributable to Clorox by component were as follows for the periods indicated:
Three Months Ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of December 31, 2019$(421)$(17)$(163)$(601)
Other comprehensive (loss) income before reclassifications(49)(9)— (58)
Amounts reclassified from Accumulated other comprehensive net (loss) income— 
Income tax benefit (expense)(2)(1)(1)
Net current period other comprehensive (loss) income(51)(5)(55)
Balance as of March 31, 2020$(472)$(22)$(162)$(656)
Balance as of December 31, 2020$(403)$(3)$(169)$(575)
Other comprehensive (loss) income before reclassifications(6)33 — 27 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 
Income tax benefit (expense), and other(1)(8)(1)(10)
Net current period other comprehensive (loss) income(7)27 22 
Balance as of March 31, 2021$(410)$24 $(167)$(553)
Nine Months Ended March 31
Foreign currency translation adjustmentsNet unrealized gains (losses) on derivativesPension and postretirement benefit adjustmentsAccumulated other comprehensive net (loss) income
Balance as of June 30, 2019$(414)$(23)$(165)$(602)
Other comprehensive (loss) income before reclassifications(55)(6)— (61)
Amounts reclassified from Accumulated other comprehensive net (loss) income— 11 
Income tax benefit (expense)(3)(2)(4)
Net current period other comprehensive (loss) income(58)(54)
Balance as of March 31, 2020$(472)$(22)$(162)$(656)
Balance as of June 30, 2020$(450)$(18)$(172)$(640)
Other comprehensive (loss) income before reclassifications38 47 — 85 
Amounts reclassified from Accumulated other comprehensive net (loss) income— 14 
Income tax benefit (expense), and other(12)(2)(12)
Net current period other comprehensive (loss) income40 42 87 
Balance as of March 31, 2021$(410)$24 $(167)$(553)
v3.21.1
EMPLOYEE BENEFIT PLANS (Tables)
9 Months Ended
Mar. 31, 2021
Retirement Benefits [Abstract]  
Schedule of Components of Net Periodic Benefit Cost
The following table summarizes the components of net periodic benefit cost for the Company’s retirement income plans:
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Service cost$— $— $— $— 
Interest cost11 15 
Expected return on plan assets (1)
(4)(5)(11)(14)
Amortization of unrecognized items
Total$$$$
(1) The weighted average long-term expected rate of return on plan assets used in computing the fiscal year 2021 net periodic benefit cost is 3.1%.
v3.21.1
SEGMENT RESULTS (Tables)
9 Months Ended
Mar. 31, 2021
Segment Reporting [Abstract]  
Selected Financial Information Relating to the Company's Segments
The tables below present reportable segment information and a reconciliation of the segment information to the Company’s consolidated Net sales and Earnings before income taxes, with amounts that are not allocated to the reportable segments reflected in Corporate.
Net sales
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Health and Wellness$680 $736 $2,310 $1,944 
Household510 480 1,421 1,183 
Lifestyle293 294 928 856 
International298 273 880 755 
Corporate— — — — 
Total$1,781 $1,783 $5,539 $4,738 
Earnings (losses) before income taxes
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Health and Wellness (1)
$(183)$210 $315 $514 
Household97 114 266 190 
Lifestyle68 80 259 242 
International30 36 184 106 
Corporate(71)(143)(225)(262)
Total$(59)$297 $799 $790 
(1) The earnings (losses) before income taxes for the Health and Wellness segment include a $329 non-cash goodwill, trademark and other asset impairment charge for the VMS SBU for the three and nine months ended March 31, 2021.
The following table provides Net sales as a percentage of the Company’s consolidated net sales for the Company’s SBUs and for the periods indicated:
Net sales
Three Months EndedNine Months Ended
3/31/20213/31/20203/31/20213/31/2020
Cleaning29 %32 %30 %31 %
Professional Products%%%%
Vitamins, Minerals and Supplements%%%%
Health and Wellness38 %42 %41 %41 %
Bags and Wraps11 %11 %11 %12 %
Cat Litter%%%%
Grilling11 %%%%
Household29 %27 %26 %25 %
Food Products10 %%%%
Natural Personal Care%%%%
Water Filtration%%%%
Lifestyle16 %16 %17 %18 %
International17 %15 %16 %16 %
Total100 %100 %100 %100 %
v3.21.1
BUSINESS ACQUIRED (Narrative) (Details) - USD ($)
3 Months Ended 6 Months Ended 9 Months Ended
Jul. 09, 2020
Mar. 31, 2021
Dec. 31, 2020
Mar. 31, 2021
Sep. 30, 2020
Jun. 30, 2020
Business Combination, Separately Recognized Transactions [Line Items]            
Total purchase consideration $ 111,000,000          
Cash paid 100,000,000          
Loss on settlement 11,000,000          
Goodwill   $ 1,574,000,000 $ 1,803,000,000 $ 1,574,000,000 $ 1,793,000,000 $ 1,577,000,000
Non-recurring, non-cash gain     $ 85,000,000      
Joint venture net sales   $ 19,000,000   $ 65,000,000    
Joint Venture In Kingdom Of Saudi Arabia            
Business Combination, Separately Recognized Transactions [Line Items]            
Total purchase consideration 111,000,000          
Goodwill 208,000,000          
Goodwill deductible for tax purposes $ 0          
The weighted-average estimated useful life of intangible assets subject to amortization 9 years          
Joint Venture In Kingdom Of Saudi Arabia            
Business Combination, Separately Recognized Transactions [Line Items]            
Noncontrolling interest, ownership percentage by parent 51.00%          
Joint Venture In Kingdom Of Saudi Arabia            
Business Combination, Separately Recognized Transactions [Line Items]            
Equity method investment, ownership percentage 30.00%          
Equity method investments $ 27,000,000          
v3.21.1
BUSINESS ACQUIRED (Fair Value Of Assets Acquired and Liabilities Assumed) (Details) - USD ($)
$ in Millions
Jul. 09, 2020
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Jun. 30, 2020
Business Combination, Separately Recognized Transactions [Line Items]          
Goodwill   $ 1,574 $ 1,803 $ 1,793 $ 1,577
Total purchase consideration $ 111        
Joint Venture In Kingdom Of Saudi Arabia          
Business Combination, Separately Recognized Transactions [Line Items]          
Goodwill 208        
Property, plant and equipment 46        
Working capital, net (includes cash acquired of $26) 34        
Noncurrent liabilities, net (5)        
Deferred income taxes (19)        
Total fair value of net assets 412        
Less: Fair value of noncontrolling interests (198)        
Less: Fair value of previously held equity interest (103)        
Total purchase consideration 111        
Cash acquired 26        
Contractual Rights [Member] | Joint Venture In Kingdom Of Saudi Arabia          
Business Combination, Separately Recognized Transactions [Line Items]          
Reacquired rights (included in Other intangible assets, net) 138        
Customer relationships (included in Other intangible assets, net) 138        
Customer Relationships [Member] | Joint Venture In Kingdom Of Saudi Arabia          
Business Combination, Separately Recognized Transactions [Line Items]          
Reacquired rights (included in Other intangible assets, net) 10        
Customer relationships (included in Other intangible assets, net) $ 10        
v3.21.1
INVENTORIES, NET (Details) - USD ($)
$ in Millions
Mar. 31, 2021
Jun. 30, 2020
Inventory Disclosure [Abstract]    
Finished goods $ 522 $ 340
Raw materials and packaging 188 140
Work in process 10 7
LIFO allowances (32) (33)
Total $ 688 $ 454
v3.21.1
GOODWILL, TRADEMARK AND OTHER ASSETS IMPAIRMENTS (Schedule of Impairment) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Finite-Lived Intangible Assets [Line Items]        
Goodwill impairment $ 228      
Property, plant and equipment, net 1      
Goodwill, trademark and other asset impairments 329 $ 0 $ 329 $ 0
Other Intangible Assets        
Finite-Lived Intangible Assets [Line Items]        
Impairment of intangible assets 14      
Trademarks        
Finite-Lived Intangible Assets [Line Items]        
Impairment of intangible assets $ 86      
v3.21.1
GOODWILL, TRADEMARK AND OTHER ASSETS IMPAIRMENTS (Additional Information) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Jun. 30, 2020
Finite-Lived Intangible Assets [Line Items]          
Impairment, tax benefit     $ (62)    
Amortization of intangible assets $ 8 $ 3 23 $ 10  
Amortization, remainder of fiscal year 8   8    
Amortization, year one 32   32    
Amortization, year two 30   30    
Amortization, year three 29   29    
Amortization, year four 28   28    
Impaired Trademarks          
Finite-Lived Intangible Assets [Line Items]          
Not subject to amortization 13   13    
Trademarks          
Finite-Lived Intangible Assets [Line Items]          
Not subject to amortization $ 683   $ 683   $ 766
Trademarks | Weighted Average          
Finite-Lived Intangible Assets [Line Items]          
Useful life     16 years    
v3.21.1
GOODWILL, TRADEMARK AND OTHER ASSETS IMPAIRMENTS (Schedule of Goodwill) (Details) - USD ($)
$ in Millions
3 Months Ended
Mar. 31, 2021
Dec. 31, 2020
Sep. 30, 2020
Goodwill [Roll Forward]      
Goodwill, Beginning Balance $ 1,803 $ 1,793 $ 1,577
Acquisitions     212
Translation adjustments and other (1) 10 4
Goodwill impairment (228)    
Goodwill, Ending Balance 1,574 1,803 1,793
Joint Venture In Kingdom Of Saudi Arabia      
Goodwill [Roll Forward]      
Translation adjustments and other   (4)  
Health and Wellness      
Goodwill [Roll Forward]      
Goodwill, Beginning Balance 857 857 857
Acquisitions     0
Translation adjustments and other 0 0 0
Goodwill impairment (228)    
Goodwill, Ending Balance 629 857 857
Household      
Goodwill [Roll Forward]      
Goodwill, Beginning Balance 85 85 85
Acquisitions     0
Translation adjustments and other 0 0 0
Goodwill impairment 0    
Goodwill, Ending Balance 85 85 85
Lifestyle      
Goodwill [Roll Forward]      
Goodwill, Beginning Balance 244 244 244
Acquisitions     0
Translation adjustments and other 0 0 0
Goodwill impairment 0    
Goodwill, Ending Balance 244 244 244
International      
Goodwill [Roll Forward]      
Goodwill, Beginning Balance 617 607 391
Acquisitions     212
Translation adjustments and other (1) 10 4
Goodwill impairment 0    
Goodwill, Ending Balance $ 616 $ 617 $ 607
v3.21.1
GOODWILL, TRADEMARK AND OTHER ASSETS IMPAIRMENTS (Intangible Assets) (Details) - USD ($)
$ in Millions
9 Months Ended 12 Months Ended
Mar. 31, 2021
Jun. 30, 2020
Finite-Lived Intangible Assets [Line Items]    
Subject to amortization, accumulated amortization $ 459 $ 343
Intangible assets, gross 1,399 1,237
Intangible assets, net 940 894
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Not subject to amortization, before impairment 769  
Not subject to amortization 683 766
Trademarks    
Finite-Lived Intangible Assets [Line Items]    
Intangible asset impairment 86 0
Subject to amortization, gross 47 47
Subject to amortization, accumulated amortization 36 28
Subject to amortization, net 11 19
Other Intangible Assets    
Finite-Lived Intangible Assets [Line Items]    
Subject to amortization, gross 583 424
Subject to amortization, accumulated amortization 337 315
Subject to amortization, net $ 246 $ 109
v3.21.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Narrative) (Details) - USD ($)
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Jun. 30, 2020
Derivative [Line Items]          
Maximum duration, foreign exchange contracts     2 years    
Estimated amount of the existing net gain (loss) to be reclassified into earnings in the next 12 months     $ 2,000,000    
Derivative instruments subject to contractually defined counterparty liability position limits $ 1,000,000   1,000,000   $ 3,000,000
Goodwill, trademark and other asset impairments 329,000,000 $ 0 329,000,000 $ 0  
Goodwill impairment 228,000,000        
Trademarks          
Derivative [Line Items]          
Impairment of intangible assets 86,000,000        
Other Assets          
Derivative [Line Items]          
Goodwill, trademark and other asset impairments 15,000,000        
Health and Wellness          
Derivative [Line Items]          
Goodwill impairment 228,000,000        
Interest Rate Contract          
Derivative [Line Items]          
Notional amount 300,000,000   $ 300,000,000   225,000,000
Maximum duration, interest rate contracts     3 years    
Purchases of Inventory | Foreign Exchange Contract          
Derivative [Line Items]          
Notional amount 68,000,000   $ 68,000,000   70,000,000
Total Commodity Purchase Derivative Contracts          
Derivative [Line Items]          
Maximum duration, commodity contracts     2 years    
Notional amount 24,000,000   $ 24,000,000   27,000,000
Soybean Oil Futures          
Derivative [Line Items]          
Notional amount 15,000,000   15,000,000   14,000,000
Soybean Oil Futures | Commodity Contract          
Derivative [Line Items]          
Cash margin balances amount 0   0   2,000,000
Jet Fuel Swaps          
Derivative [Line Items]          
Notional amount $ 9,000,000   $ 9,000,000   $ 13,000,000
v3.21.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of the Effects of Derivative Instruments Designated as Hedging Instruments) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income $ 33 $ (9) $ 47 $ (6)
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings (2) (2) (7) (6)
Commodity Contract        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income 5 (11) 12 (8)
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 0 0 (2) (1)
Foreign Exchange Contract        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income 2 2 (1) 2
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings 0 0 0 0
Interest Rate Contract        
Derivative Instruments, Gain (Loss) [Line Items]        
Gains (losses) recognized in Other comprehensive (loss) income 26 0 36 0
Gains (losses) reclassified from Accumulated other comprehensive net (loss) income and recognized in Net earnings $ (2) $ (2) $ (5) $ (5)
v3.21.1
FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Schedule of Assets and Liabilities for Fair Value Disclosure) (Details) - USD ($)
$ in Millions
Mar. 31, 2021
Jun. 30, 2020
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents $ 492 $ 871
Total assets 6,441 6,213
Total liabilities 5,503 5,305
Reported Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 42 1
Derivative liabilities 1 5
Total assets 490 849
Total liabilities 2,783 2,780
Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 42 1
Derivative liabilities 1 5
Total other assets in the fair value hierarchy 490 849
Total other liabilities in the fair value hierarchy 2,944 3,051
Other Current Assets | Fair Value, Inputs, Level 1 | Reported Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 3 0
Other Current Assets | Fair Value, Inputs, Level 1 | Estimate of Fair Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 3 0
Other Current Assets | Fair Value, Inputs, Level 2 | Reported Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 2 0
Other Current Assets | Fair Value, Inputs, Level 2 | Estimate of Fair Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 2 0
Other Assets | Fair Value, Inputs, Level 2 | Reported Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 0 0
Other Assets | Fair Value, Inputs, Level 2 | Reported Value Measurement | Interest Rate Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 37 1
Other Assets | Fair Value, Inputs, Level 2 | Estimate of Fair Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 0 0
Other Assets | Fair Value, Inputs, Level 2 | Estimate of Fair Value Measurement | Interest Rate Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative assets 37 1
Other Assets | Trust Assets for nonqualified deferred compensation plans | Fair Value, Inputs, Level 1 | Reported Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Trust assets for nonqualified deferred compensation plans 131 100
Other Assets | Trust Assets for nonqualified deferred compensation plans | Fair Value, Inputs, Level 1 | Estimate of Fair Value Measurement    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Trust assets for nonqualified deferred compensation plans 131 100
Accounts Payable and Accrued Liabilities | Fair Value, Inputs, Level 1 | Reported Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 0 1
Accounts Payable and Accrued Liabilities | Fair Value, Inputs, Level 1 | Estimate of Fair Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 0 1
Accounts Payable and Accrued Liabilities | Fair Value, Inputs, Level 2 | Reported Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 0 3
Accounts Payable and Accrued Liabilities | Fair Value, Inputs, Level 2 | Reported Value Measurement | Foreign Exchange Forward Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 1 1
Accounts Payable and Accrued Liabilities | Fair Value, Inputs, Level 2 | Estimate of Fair Value Measurement | Commodity Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 0 3
Accounts Payable and Accrued Liabilities | Fair Value, Inputs, Level 2 | Estimate of Fair Value Measurement | Foreign Exchange Forward Contract    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Derivative liabilities 1 1
Cash and Cash Equivalents | Fair Value, Inputs, Level 1 | Reported Value Measurement | Investments, including money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 213 584
Cash and Cash Equivalents | Fair Value, Inputs, Level 1 | Estimate of Fair Value Measurement | Investments, including money market funds    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 213 584
Cash and Cash Equivalents | Fair Value, Inputs, Level 2 | Reported Value Measurement | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 146 165
Cash and Cash Equivalents | Fair Value, Inputs, Level 2 | Estimate of Fair Value Measurement | Time deposits    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Cash and cash equivalents 146 165
Current maturities of long-term debt and Long-term debt | Fair Value, Inputs, Level 2 | Reported Value Measurement | Long-term Debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current maturities of long-term debt and Long-term debt 2,783 2,780
Current maturities of long-term debt and Long-term debt | Fair Value, Inputs, Level 2 | Estimate of Fair Value Measurement | Long-term Debt    
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]    
Current maturities of long-term debt and Long-term debt $ 2,944 $ 3,051
v3.21.1
INCOME TAXES (Narrative) (Details)
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Income Tax Disclosure [Abstract]        
Effective tax rate on earnings from continuing operations (1.40%) 18.90% 22.50% 20.40%
v3.21.1
NET EARNINGS (LOSSES) PER SHARE (EPS) (Schedule of Weighted Average Number of Shares) (Details) - shares
shares in Thousands
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Earnings Per Share [Abstract]        
Basic (in shares) 125,610 125,661 126,057 125,641
Dilutive effect of stock options and other (in shares) 0 1,667 1,973 1,595
Diluted (in shares) 125,610 127,328 128,030 127,236
Antidilutive stock options and other (in shares) 4,826 0 428 2
v3.21.1
NET EARNINGS (LOSSES) PER SHARE (EPS) (Dividends Per Share Declared) (Details) - $ / shares
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Earnings Per Share [Abstract]        
Dividends declared per share (in dollars per share) $ 1.11 $ 1.06 $ 3.33 $ 3.18
v3.21.1
COMPREHENSIVE INCOME (LOSS) (Schedule of Comprehensive Income) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Stockholders' Equity Note [Abstract]        
Net earnings $ (59) $ 241 $ 619 $ 629
Other comprehensive (loss) income, net of tax:        
Foreign currency translation adjustments (7) (51) 40 (58)
Net unrealized gains (losses) on derivatives 27 (5) 42 1
Pension and postretirement benefit adjustments 2 1 5 3
Total other comprehensive (loss) income, net of tax 22 (55) 87 (54)
Comprehensive income (loss) (37) 186 706 575
Less: Total comprehensive income attributable to noncontrolling interests 2 0 6 0
Total comprehensive income (loss) attributable to Clorox $ (39) $ 186 $ 700 $ 575
v3.21.1
STOCKHOLDERS' EQUITY (Schedule of Equity) (Details) - USD ($)
$ / shares in Units, shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Nov. 18, 2020
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Class of Stock [Line Items]          
Dividends declared per share (in dollars per share)   $ 1.11 $ 1.06 $ 3.33 $ 3.18
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Balance, beginning   $ 1,380 $ 555 $ 908 $ 559
Net earnings (losses)   (59) 241 619 629
Other comprehensive (loss) income   22 (55) 87 (54)
Dividends   (139) (135) (421) (402)
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders   (3)   (9)  
Business combinations including purchase accounting adjustments       198  
Stock-based compensation   17 18 52 37
Other employee stock plan activities   25 101 109 123
Treasury stock purchased   $ (305) $ (30) $ (605) $ (219)
Treasury stock purchased (in shares)   (1,648) (184) (3,072) (1,424)
Treasury stock retirement       $ 0  
Balance, ending   $ 938 $ 695 938 $ 695
Cumulative Effect of Accounting Changes, Net of Tax [Member]          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Balance, beginning         22
Common Stock [Member]          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Balance, beginning   $ 131 $ 159 $ 159 $ 159
Balance, beginning (in shares)   130,741 158,741 158,741 158,741
Treasury stock retirement       $ (28)  
Treasury stock retirement (in shares)       28,000  
Balance, ending   $ 131 $ 159 $ 131 $ 159
Balance, ending (in shares)   130,741 158,741 130,741 158,741
Additional Paid-in Capital [Member]          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Balance, beginning   $ 1,176 $ 1,062 $ 1,137 $ 1,046
Stock-based compensation   17 18 52 37
Other employee stock plan activities   (3) 31 1 28
Balance, ending   1,190 1,111 1,190 1,111
Retained Earnings [Member]          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Balance, beginning   1,302 3,292 3,567 3,150
Net earnings (losses)   (61) 241 613 629
Dividends   (139) (135) (421) (402)
Other employee stock plan activities   (16) 0 (33) (1)
Treasury stock retirement       (2,640)  
Balance, ending   1,086 3,398 1,086 3,398
Retained Earnings [Member] | Cumulative Effect of Accounting Changes, Net of Tax [Member]          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Balance, beginning         22
Treasury Stock [Member]          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Balance, beginning   $ (850) $ (3,357) $ (3,315) $ (3,194)
Balance, beginning (in shares)   5,017 33,717 32,543 33,055
Other employee stock plan activities   $ 44 $ 70 $ 141 $ 96
Other employee stock plan activities (in shares)   283 1,083 1,233 1,661
Treasury stock purchased   $ (305) $ (30) $ (605) $ (219)
Treasury stock purchased (in shares)   (1,648) (184) (3,072) (1,424)
Treasury stock retirement       $ 2,668  
Treasury stock retirement (in shares) 28,000     28,000  
Balance, ending   $ (1,111) $ (3,317) $ (1,111) $ (3,317)
Balance, ending (in shares)   6,382 32,818 6,382 32,818
Accumulated other comprehensive net (loss) income [Member]          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Balance, beginning   $ (575) $ (601) $ (640) $ (602)
Other comprehensive (loss) income   22 (55) 87 (54)
Balance, ending   (553) (656) (553) (656)
Noncontrolling Interest [Member]          
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Balance, beginning   196 0 0 0
Net earnings (losses)   2   6  
Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders   (3)   (9)  
Business combinations including purchase accounting adjustments       198  
Treasury stock retirement       0  
Balance, ending   $ 195 $ 0 $ 195 $ 0
v3.21.1
STOCKHOLDERS' EQUITY (Narrative) (Details)
shares in Thousands
3 Months Ended 9 Months Ended
Nov. 18, 2020
shares
Mar. 31, 2021
USD ($)
repurchaseProgram
Mar. 31, 2020
USD ($)
Mar. 31, 2021
USD ($)
repurchaseProgram
shares
Mar. 31, 2020
USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Number of repurchase programs | repurchaseProgram   2   2  
Amounts reclassified from accumulated other comprehensive net (loss) income   $ (5,000,000) $ (4,000,000) $ (14,000,000) $ (11,000,000)
Long-Term Inter-Company Loans [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Amounts reclassified from accumulated other comprehensive net (loss) income   0 $ 0 $ 0 $ 0
Treasury Stock [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Treasury stock retired | shares 28,000     28,000  
$2 Billion Open-Market Purchase Program [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Stock repurchase program, authorized amount   2,000,000,000   $ 2,000,000,000  
Evergreen Program [Member]          
Accumulated Other Comprehensive Income (Loss) [Line Items]          
Authorization limit   $ 0   $ 0  
v3.21.1
STOCKHOLDERS' EQUITY (Share Repurchase Programs) (Details) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Share Repurchase Programs [Line Items]        
Value of shares repurchased $ 305 $ 30 $ 605 $ 219
Shares repurchased (in shares) 1,648 184 3,072 1,424
$2 Billion Open-Market Purchase Program [Member]        
Share Repurchase Programs [Line Items]        
Value of shares repurchased $ 200 $ 0 $ 200 $ 85
Shares repurchased (in shares) 1,088 0 1,088 577
Evergreen Program [Member]        
Share Repurchase Programs [Line Items]        
Value of shares repurchased $ 105 $ 30 $ 405 $ 134
Shares repurchased (in shares) 560 184 1,984 847
v3.21.1
STOCKHOLDERS' EQUITY (Schedule of Changes in Accumulated Other Comprehensive Net (Losses) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Balance, beginning     $ 908  
Other comprehensive (loss) income before reclassifications $ 27 $ (58) 85 $ (61)
Amounts reclassified from Accumulated other comprehensive net (loss) income 5 4 14 11
Income tax benefit (expense) (10) (1) (12) (4)
Net current period other comprehensive (loss) income 22 (55) 87 (54)
Balance, ending 743   743  
Foreign currency translation adjustments [Member]        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Balance, beginning (403) (421) (450) (414)
Other comprehensive (loss) income before reclassifications (6) (49) 38 (55)
Amounts reclassified from Accumulated other comprehensive net (loss) income 0 0 0 0
Income tax benefit (expense) (1) (2) 2 (3)
Net current period other comprehensive (loss) income (7) (51) 40 (58)
Balance, ending (410) (472) (410) (472)
Net unrealized gains (losses) on derivatives [Member]        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Balance, beginning (3) (17) (18) (23)
Other comprehensive (loss) income before reclassifications 33 (9) 47 (6)
Amounts reclassified from Accumulated other comprehensive net (loss) income 2 2 7 6
Income tax benefit (expense) (8) 2 (12) 1
Net current period other comprehensive (loss) income 27 (5) 42 1
Balance, ending 24 (22) 24 (22)
Pension and postretirement benefit adjustments [Member]        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Balance, beginning (169) (163) (172) (165)
Other comprehensive (loss) income before reclassifications 0 0 0 0
Amounts reclassified from Accumulated other comprehensive net (loss) income 3 2 7 5
Income tax benefit (expense) (1) (1) (2) (2)
Net current period other comprehensive (loss) income 2 1 5 3
Balance, ending (167) (162) (167) (162)
Accumulated other comprehensive net (loss) income [Member]        
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]        
Balance, beginning (575) (601) (640) (602)
Balance, ending $ (553) $ (656) $ (553) $ (656)
v3.21.1
EMPLOYEE BENEFIT PLANS (Components of the Net Cost of Retirement Income (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Defined Benefit Plan Disclosure [Line Items]        
Total $ 0 $ 0 $ (1) $ (1)
Weighted average long-term expected rate or return on plan assets     3.10%  
Other Postretirement Benefits Plan [Member] | Retirement Income Plans [Member]        
Defined Benefit Plan Disclosure [Line Items]        
Service cost 0 0 $ 0 0
Interest cost 4 5 11 15
Expected return on plan assets (4) (5) (11) (14)
Amortization of unrecognized items 3 3 8 7
Total $ 3 $ 3 $ 8 $ 8
v3.21.1
EMPLOYEE BENEFIT PLANS (Narrative) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Defined Benefit Plan Disclosure [Line Items]        
Net periodic benefit cost (benefit) $ 0 $ 0 $ (1) $ (1)
Retirement Income Plans [Member] | UNITED STATES        
Defined Benefit Plan Disclosure [Line Items]        
Discretionary contributions $ 6 $ 7 $ 10 $ 10
v3.21.1
OTHER CONTINGENCIES AND GUARANTEES (Details) - USD ($)
$ in Millions
9 Months Ended
Mar. 31, 2021
Jun. 30, 2020
Jun. 30, 2017
Loss Contingencies [Line Items]      
Liability for aggregate future remediation costs $ 27 $ 28  
Letter of credit 11    
Letter of credit, amount outstanding 0    
Alameda County, California Matter [Member]      
Loss Contingencies [Line Items]      
Liability for aggregate future remediation costs $ 14 14 $ 14
Remediation period 30 years    
Maximum undiscounted costs $ 28    
Dickinson County, Michigan Matter [Member]      
Loss Contingencies [Line Items]      
Liability for aggregate future remediation costs $ 10 $ 10  
Remediation period 30 years    
Percentage of liability for aggregate remediation and associated costs, other than legal fees 24.30%    
v3.21.1
SEGMENT RESULTS (Narrative) (Details) - reportableSegment
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Concentration Risk [Line Items]        
Number of reportable segments     4  
Revenue from Contract with Customer [Member] | Customer Concentration Risk [Member] | Walmart Stores, Inc. [Member]        
Concentration Risk [Line Items]        
Concentration percentage 24.00% 25.00% 24.00% 25.00%
v3.21.1
SEGMENT RESULTS (Selected Financial Information Relating To Company's Segments ) (Details) - USD ($)
$ in Millions
3 Months Ended 9 Months Ended
Mar. 31, 2021
Mar. 31, 2020
Mar. 31, 2021
Mar. 31, 2020
Segment Reporting Information [Line Items]        
Net sales $ 1,781 $ 1,783 $ 5,539 $ 4,738
Earnings (losses) before income taxes (59) $ 297 $ 799 $ 790
Goodwill impairment $ 228      
Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 100.00% 100.00% 100.00% 100.00%
Health and Wellness        
Segment Reporting Information [Line Items]        
Goodwill impairment $ 228      
Health and Wellness | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 38.00% 42.00% 41.00% 41.00%
Health and Wellness | Cleaning [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 29.00% 32.00% 30.00% 31.00%
Health and Wellness | Professional Products [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 5.00% 6.00% 7.00% 6.00%
Health and Wellness | Vitamins, Minerals and Supplements [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 4.00% 4.00% 4.00% 4.00%
Household        
Segment Reporting Information [Line Items]        
Goodwill impairment $ 0      
Household | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 29.00% 27.00% 26.00% 25.00%
Household | Bags and Wraps [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 11.00% 11.00% 11.00% 12.00%
Household | Cat Litter [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 7.00% 7.00% 7.00% 7.00%
Household | Grilling [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 11.00% 9.00% 8.00% 6.00%
Lifestyle        
Segment Reporting Information [Line Items]        
Goodwill impairment $ 0      
Lifestyle | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 16.00% 16.00% 17.00% 18.00%
Lifestyle | Food Products [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 10.00% 8.00% 9.00% 9.00%
Lifestyle | Natural Personal Care [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 3.00% 4.00% 4.00% 5.00%
Lifestyle | Water Filtration [Member] | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 3.00% 4.00% 4.00% 4.00%
International        
Segment Reporting Information [Line Items]        
Goodwill impairment $ 0      
International | Product Concentration Risk [Member] | Revenue from Contract with Customer [Member]        
Segment Reporting Information [Line Items]        
Concentration percentage 17.00% 15.00% 16.00% 16.00%
Operating Segments [Member] | Health and Wellness        
Segment Reporting Information [Line Items]        
Net sales $ 680 $ 736 $ 2,310 $ 1,944
Earnings (losses) before income taxes (183) 210 315 514
Operating Segments [Member] | Household        
Segment Reporting Information [Line Items]        
Net sales 510 480 1,421 1,183
Earnings (losses) before income taxes 97 114 266 190
Operating Segments [Member] | Lifestyle        
Segment Reporting Information [Line Items]        
Net sales 293 294 928 856
Earnings (losses) before income taxes 68 80 259 242
Operating Segments [Member] | International        
Segment Reporting Information [Line Items]        
Net sales 298 273 880 755
Earnings (losses) before income taxes 30 36 184 106
Corporate, Non-Segment [Member]        
Segment Reporting Information [Line Items]        
Net sales 0 0 0 0
Earnings (losses) before income taxes $ (71) $ (143) $ (225) $ (262)